9.43
Organon Co stock is traded at $9.43, with a volume of 3.55M.
It is up +1.62% in the last 24 hours and down -3.97% over the past month.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
See More
Previous Close:
$9.28
Open:
$9.39
24h Volume:
3.55M
Relative Volume:
0.83
Market Cap:
$2.45B
Revenue:
$6.29B
Net Income/Loss:
$750.00M
P/E Ratio:
3.2743
EPS:
2.88
Net Cash Flow:
$586.00M
1W Performance:
-0.11%
1M Performance:
-3.97%
6M Performance:
-39.12%
1Y Performance:
-54.86%
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Compare OGN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
OGN
Organon Co
|
9.43 | 2.41B | 6.29B | 750.00M | 586.00M | 2.88 |
![]()
LLY
Lilly Eli Co
|
711.68 | 625.77B | 53.26B | 13.80B | -50.20M | 15.30 |
![]()
JNJ
Johnson Johnson
|
179.29 | 424.47B | 90.62B | 22.66B | 18.18B | 9.35 |
![]()
ABBV
Abbvie Inc
|
210.60 | 364.92B | 58.33B | 3.73B | 18.24B | 2.10 |
![]()
NVS
Novartis Ag Adr
|
126.98 | 240.07B | 53.40B | 13.68B | 16.89B | 6.9231 |
![]()
MRK
Merck Co Inc
|
87.37 | 210.36B | 63.43B | 16.42B | 14.72B | 6.49 |
Organon Co Stock (OGN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-02-25 | Downgrade | Evercore ISI | Outperform → In-line |
Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
Sep-21-23 | Initiated | Barclays | Overweight |
Mar-16-23 | Initiated | Raymond James | Outperform |
Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
Apr-27-22 | Initiated | Goldman | Buy |
Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
Oct-07-21 | Initiated | Piper Sandler | Neutral |
Sep-01-21 | Initiated | BofA Securities | Buy |
Jul-22-21 | Initiated | Citigroup | Buy |
Jun-15-21 | Initiated | JP Morgan | Neutral |
Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
Henlius And Organon Sued In US Over Plans To Market Perjeta Biosimilar - insights.citeline.com
Does Organon's Raised 2025 Guidance Signal a Turning Point for OGN Investors? - simplywall.st
Kahn Brothers' Q2 2025 13F Filing: Alphabet, Comcast, and Organon Highlights - AInvest
Organon in charts: Women's Health revenue up ~3% Y/Y in Q2 - MSN
Roche Sues Organon in First Case Over Biosimilar Copy of Perjeta - Bloomberg Law News
There May Be Some Bright Spots In Organon's (NYSE:OGN) Earnings - Yahoo Finance
Organon & Co. (OGN) Stock Price, News & Analysis - MarketBeat
Daré Bioscience Posts Narrower Q2 Loss - The Motley Fool
OGN’s Market Whiplash: -52.64% YTD Decline, -4.30% Plunge in 30 Days - investchronicle.com
Bullish Organon Insiders Loaded Up On US$651.6k Of Stock - 富途牛牛
Organon & Co.'s Q2 2025 Earnings Call: Unraveling Key Contradictions in Capital Allocation, Nexplanon Growth, and Financial Forecasts - AInvest
LPL Financial LLC Has $4.87 Million Holdings in Organon & Co. (NYSE:OGN) - Defense World
NYSE: OGN Lawsuit Alert: Investors who lost money with Organon & Co. (NYSE: OGN) shares should contact the Shareholders Foundation - The Malaysian Reserve
Ex-Dividend Reminder: Cencora, Organon and Esquire Financial Holdings - Nasdaq
5 Must-Read Analyst Questions From Organon’s Q2 Earnings Call - Yahoo Finance
OGN Q2 Deep Dive: Flat Sales, Margin Pressure, and Strategic Shifts Highlight Quarter - Yahoo Finance
Organon's Valuation: Discounted Due to Structural Challenges - AInvest
Organon: Valuation Discount Offset By Structural Headwinds (NYSE:OGN) - Seeking Alpha
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - MSN
Natixis Advisors LLC Has $778,000 Holdings in Organon & Co. (NYSE:OGN) - Defense World
Organon & Co. (OGN): Assessing Dividend Sustainability and Valuation Amid Earnings Pressures and Strategic Catalysts - AInvest
Read This Before Considering Organon & Co. (NYSE:OGN) For Its Upcoming US$0.02 Dividend - uk.finance.yahoo.com
Organon & Co. (OGN) Reports Q2 2025 Results - MSN
Organon Q2 Preview: What to expect? - MSN
Organon & Co. (NYSE:OGN) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Organon & Co. Reports Q2 2025 Earnings, Raises Full-Year Guidance - AInvest
Organon & Co. (NYSE:OGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
Organon & Co. Reports Q2 2025 Financial Results - The Globe and Mail
Organon & Co. Earnings Call: Resilience Amid Challenges - The Globe and Mail
Organon (OGN) Fiscal Q2 Revenue Beats 1% - AOL.com
Organon & Co. (OGN) Slashes 13.13% on Disappointing Earnings - MSN
Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade) (NYSE:OGN) - Seeking Alpha
Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences - The Globe and Mail
Organon & Co. SEC 10-Q Report - TradingView
Organon & Co. (NYSE:OGN) Q2 2025 Earnings Call Transcript - Insider Monkey
Organon jumps despite Q2 revenue dip as revised outlook exceeds consensus - MSN
Organon Reports Results for the Second Quarter Ended June 30, 2025 - BioSpace
ORGANON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co.OGN - Discover 361
Organon & Co. shares rise 1.67% premarket after beating Q2 revenue expectations and raising FY guidance. - AInvest
Organon & Co (OGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth By GuruFocus - Investing.com Canada
Organon: Q2 Earnings Snapshot - Norwalk Hour
Organon raises 2025 revenue guidance by $100M amid Vtama ramp and debt reduction focus - MSN
Organon & Co To Go Ex-Dividend On August 15th, 2025 With 0.02 USD Dividend Per Share - 富途牛牛
Organon reports Q2 adjusted EPS $1.00, consensus 94c - TipRanks
Organon raises FY25 revenue view to $6.28B-$6.38B from $6.13B-$6.33B - TipRanks
OGN Shares Plunge: Lawsuit Drives Market Shock - StocksToTrade
Organon & Co. 2025 Q2ResultsEarnings Call Presentation (NYSE:OGN) - Seeking Alpha
Earnings call transcript: Organon Q2 2025 beats EPS expectations, stock volatile - Investing.com
Organon Becomes Oversold - Nasdaq
Organon (OGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Organon & Co. Reports Strong Q2 Earnings, Surpassing ExpectationsNews and Statistics - IndexBox
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Organon Co Stock (OGN) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
COX CARRIE SMITH | Director |
May 14 '25 |
Buy |
8.07 |
12,469 |
100,591 |
12,469 |
Falcione Aaron | Chief Human Resources Officer |
May 07 '25 |
Buy |
8.77 |
5,500 |
48,235 |
62,974 |
Weaver Kirke | Gen. Counsel & Corp. Secy. |
May 06 '25 |
Buy |
9.21 |
8,045 |
74,054 |
52,489 |
Karp Daniel | Executive VP, Corp. Dev. |
May 06 '25 |
Buy |
8.24 |
3,500 |
28,828 |
46,669 |
WALSH MATTHEW M | Chief Financial Officer |
May 05 '25 |
Buy |
8.82 |
11,400 |
100,548 |
144,484 |
Ali Kevin | Chief Executive Officer |
May 05 '25 |
Buy |
8.80 |
34,000 |
299,370 |
282,731 |
Falcione Aaron | Chief Human Resources Officer |
Mar 31 '25 |
Option Exercise |
0.00 |
18,732 |
0 |
59,237 |
Karp Daniel | Executive VP, Corp. Dev. |
Mar 31 '25 |
Option Exercise |
0.00 |
34,677 |
0 |
44,515 |
Stahler Rachel A | Chief Information Officer |
Mar 31 '25 |
Option Exercise |
0.00 |
18,334 |
0 |
78,994 |
WALSH MATTHEW M | Chief Financial Officer |
Mar 31 '25 |
Option Exercise |
0.00 |
34,870 |
0 |
136,903 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):